Gilead Sciences is betting that a MacroGenics antibody drug for blood cancers can offer a safety edge over others that address the same target. It’s the second partnership between the two companies; an alliance that began in 2013 expired without Gilead licensing any molecules from the deal.
In a conference call with analysts, the company's CEO was tight-lipped about the median improvement in PFS, but the results nevertheless beat many investors' expectations.
Innovative sterilization cases and trays are instrumental in reducing infection risk in medical settings. Learn notable things about them and their makers.
Two trials involving the drug MGD009 - a monotherapy study and one in combination with the company's PD-1 inhibitor - are barred from enrolling new patients pending FDA review and a planned protocol amendment.